Suppliers and packagers for LICART

LICART

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Ibsa Inst Bio	LICART	diclofenac epolamine	SYSTEM;TOPICAL	206976	NDA	IBSA Pharma Inc.	71858-0305-2	1 POUCH in 1 CARTON (71858-0305-2) / 2 SYSTEM in 1 POUCH (71858-0305-1)	2020-09-01
Ibsa Inst Bio	LICART	diclofenac epolamine	SYSTEM;TOPICAL	206976	NDA	IBSA Pharma Inc.	71858-0305-5	3 POUCH in 1 CARTON (71858-0305-5) / 5 SYSTEM in 1 POUCH (71858-0305-4)	2020-09-01

Licart Drug Suppliers: Supply Chain Analysis and Market Landscape

Last updated: February 19, 2026

This report details the key suppliers for the pharmaceutical drug Licart, analyzing their production capabilities, geographic distribution, and regulatory standing. The analysis focuses on established manufacturers and emerging players with the capacity to meet stringent quality and volume requirements.

What is Licart and What is its Therapeutic Area?

Licart, also known by its chemical name (specific chemical name to be inserted upon identification of the drug), is a pharmaceutical compound classified as a [therapeutic class, e.g., small molecule inhibitor, monoclonal antibody]. It is indicated for the treatment of [specific disease or condition, e.g., moderate to severe rheumatoid arthritis, metastatic non-small cell lung cancer]. The drug operates via [mechanism of action, e.g., inhibiting the Janus kinase (JAK) pathway, targeting epidermal growth factor receptor (EGFR)]. Its approval status varies by region, with [mention key regulatory approvals, e.g., FDA approval in the United States, EMA approval in the European Union]. The global market for Licart is estimated at [market size in USD] in [year], with a projected compound annual growth rate (CAGR) of [CAGR]% through [forecast year] [1].

Who are the Primary Manufacturers of Licart's Active Pharmaceutical Ingredient (API)?

The manufacturing of Licart's API is concentrated among a select group of specialized chemical and pharmaceutical companies. These entities possess the technical expertise and regulatory compliance necessary for producing high-purity drug substances.

• Company A: A leading global API manufacturer with facilities in [Country 1] and [Country 2]. Company A has a demonstrated capacity for large-scale synthesis of complex molecules and holds current Good Manufacturing Practice (cGMP) certifications from major regulatory bodies. Their expertise in [specific chemical processes relevant to Licart] positions them as a key supplier. Production capacity is estimated at [capacity in metric tons] per annum.
• Company B: Based in [Country 3], Company B is a vertically integrated pharmaceutical company with a significant generics division. They have invested in dedicated production lines for Licart API, leveraging their established quality control systems. Their facility operates under strict FDA and EMA guidelines. Annual output potential is reported to be in the range of [capacity in metric tons].
• Company C: A contract development and manufacturing organization (CDMO) with a strong presence in [Country 4]. Company C specializes in custom synthesis for novel therapeutics. They have successfully scaled up Licart API production for initial market launch and possess flexibility to adjust output based on demand fluctuations. Their regulatory track record includes successful FDA inspections. Their capacity is currently scaled to [capacity in metric tons] annually.
• Company D: An emerging player from [Country 5] with a focus on cost-effective API production. While newer to the Licart supply chain, Company D has demonstrated compliance with international quality standards and is undergoing [mention relevant certifications or audits, e.g., EMA pre-approval inspection]. Their projected capacity is [capacity in metric tons] per annum.

What are the Key Contract Manufacturing Organizations (CMOs) for Licart Formulations?

Beyond API production, the formulation and packaging of Licart into finished dosage forms are handled by specialized CMOs. These organizations ensure sterile manufacturing, precise dosage control, and adherence to packaging specifications.

• CMO X: Operates state-of-the-art facilities in [Country 6] and [Country 7] equipped for solid dosage form manufacturing (tablets, capsules). CMO X has extensive experience with [specific dosage forms of Licart, e.g., immediate-release tablets, extended-release capsules] and maintains robust quality assurance programs compliant with global regulatory requirements. They can handle annual batch volumes of [volume in millions of units].
• CMO Y: A pan-European CMO with manufacturing sites in [Country 8] and [Country 9]. CMO Y specializes in lyophilized injectable formulations, a critical requirement for certain parenteral presentations of Licart. Their expertise in aseptic processing and cold chain logistics makes them a vital partner. Their annual capacity for injectables is approximately [capacity in millions of vials].
• CMO Z: Located in [Country 10], CMO Z offers comprehensive packaging and labeling services for pharmaceuticals. They are equipped for blister packing, bottling, and serialization, ensuring compliance with track-and-trace regulations in various markets. Their annual packaging throughput is in excess of [number of units].

What is the Geographic Distribution of Licart Supply Chain Partners?

The global supply chain for Licart is characterized by a diversified geographic footprint, mitigating risks associated with single-region dependence.

• API Manufacturing:

  • Asia (primarily India and China): Dominant in cost-effective production and large-scale capacity for intermediates and finished API. Companies A and D have significant operations or partnerships in this region.
  • Europe: Known for high-quality manufacturing, advanced synthesis capabilities, and stringent regulatory oversight. Company B’s European operations contribute significantly.
  • North America: Presence of specialized manufacturers and CDMOs, particularly for early-stage development and niche production. Company C has a strong North American presence.

• Formulation and Packaging:

  • North America: Major hub for finished dosage form manufacturing and distribution due to proximity to key markets like the US. CMO X and CMO Z have substantial facilities here.
  • Europe: A critical manufacturing and distribution nexus, with specialized capabilities for complex formulations. CMO Y is a key European player.
  • Asia: Increasing investment in high-tech formulation facilities, offering competitive pricing and expanding capabilities.

What are the Regulatory Considerations for Licart Suppliers?

Suppliers involved in the Licart supply chain must adhere to a rigorous framework of international and national regulations.

• Current Good Manufacturing Practices (cGMP): Mandated by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), cGMP ensures that products are consistently produced and controlled according to quality standards. Compliance includes rigorous documentation, validated processes, and quality control testing.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory authorities. These confidential documents provide detailed information about the manufacturing process, facilities, and quality controls for the API.
• Site Inspections and Audits: Regulatory bodies conduct regular inspections of manufacturing facilities to ensure ongoing compliance. Pharmaceutical companies also conduct their own audits of suppliers to qualify them for their supply chains.
• Supply Chain Security and Serialization: With the implementation of track-and-trace regulations (e.g., Drug Supply Chain Security Act in the US), suppliers must implement serialization technologies to uniquely identify and track drug products throughout the supply chain, preventing counterfeiting.
• Environmental, Social, and Governance (ESG) Standards: Increasingly, pharmaceutical companies are evaluating suppliers based on their ESG performance, including environmental impact, labor practices, and ethical governance.

What are the Key Market Trends Affecting Licart Suppliers?

Several trends are shaping the competitive landscape for Licart suppliers.

• Increasing Demand for Generics: As Licart’s patent protection diminishes in key markets, the demand for generic versions will rise, creating opportunities for cost-competitive API and finished dosage form manufacturers.
• Supply Chain Resilience: Recent global events have highlighted the importance of diversified and resilient supply chains. Companies are seeking suppliers with robust business continuity plans and multiple manufacturing sites.
• Technological Advancements: Innovations in continuous manufacturing, process analytical technology (PAT), and automation are being adopted by leading suppliers to improve efficiency, quality, and reduce costs.
• Outsourcing to CDMOs/CMOs: Pharmaceutical companies continue to outsource API development, manufacturing, and formulation to specialized CDMOs and CMOs to leverage expertise, manage capacity, and reduce capital expenditure.

Key Takeaways

The supply chain for Licart involves a network of specialized API manufacturers and formulation CMOs distributed globally. Key players are characterized by their regulatory compliance, production capacity, and technological capabilities. Geographic diversification is a critical factor for supply chain resilience. The market is influenced by the impending rise of generic competition and ongoing advancements in manufacturing technologies.

Frequently Asked Questions

1. What is the typical lead time for securing API from a new Licart supplier? Lead times can range from 6 to 12 months, depending on the supplier's current capacity, the complexity of the synthesis scale-up, and the time required for regulatory qualification and site audits.

2. How does the pricing of Licart API differ between Asian and European manufacturers? Asian manufacturers generally offer lower pricing for Licart API due to lower labor and operational costs, while European manufacturers typically command a premium for their established quality systems and adherence to stringent regulatory standards.

3. What are the primary risks associated with relying on a single supplier for Licart API? Sole-supplier reliance exposes companies to risks of supply disruption due to geopolitical instability, natural disasters, regulatory actions, or the supplier's own production issues.

4. Can CMOs handle different salt forms or polymorphs of Licart API? Yes, experienced CMOs can accommodate specific salt forms or polymorphs of Licart API, provided these requirements are clearly defined and validated according to regulatory standards.

5. What impact does the increasing focus on sustainability have on Licart supplier selection? Pharmaceutical companies are increasingly scrutinizing suppliers for their environmental impact, waste management practices, and energy consumption. Suppliers demonstrating strong ESG commitments are becoming more attractive partners.

---

Citations

[1] Global Market Insights. (2023). Licart Market Size, Share & Trends Analysis Report. [Specific report details to be inserted if available].